Company Description
Revvity, Inc. provides health sciences solutions, technologies, and services.
The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions.
The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery.
It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names.
The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023.
Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 1937 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 11,000 |
| CEO | Prahlad Singh |
Contact Details
Address: 77 4th Avenue Waltham, Massachusetts 02451 United States | |
| Phone | 781 663 6900 |
| Website | revvity.com |
Stock Details
| Ticker Symbol | RVTY |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 31791 |
| CUSIP Number | 714046109 |
| ISIN Number | US7140461093 |
| Employer ID | 04-2052042 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Prahlad R. Singh Ph.D. | Chief Executive Officer, President and Director |
| Maxwell Krakowiak | Senior Vice President and Chief Financial Officer |
| Tajinder S. Vohra | Senior Vice President of Global Operations |
| Joel S. Goldberg | Senior Vice President of Administration, General Counsel and Secretary |
| Miriame Victor | Senior Vice President and Chief Commercial Officer |
| Anita Gonzales | Chief Accounting Officer, Vice President and Controller |
| Bryan A. Kipp | Senior Vice President of Technology and Licensing |
| Madhuri Hegde FACMG, Ph.D. | Senior Vice President and Chief Scientific Officer |
| Stephen Barr Willoughby | Senior Vice President of Investor Relations and Head of ESG |
| Magali Four | Senior Vice President and Chief People and Culture Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 16, 2026 | ARS | Filing |
| Mar 16, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 16, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 6, 2026 | PRE 14A | Other preliminary proxy statements |
| Feb 24, 2026 | 10-K | Annual Report |
| Feb 24, 2026 | 144 | Filing |
| Feb 23, 2026 | 144 | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 5, 2026 | 144 | Filing |
| Feb 5, 2026 | 144 | Filing |